PharmaCyte Biotech, Inc. PMCB
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
PharmaCyte Biotech, Inc. (PMCB) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -12%.
About PharmaCyte Biotech
PharmaCyte Biotech is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 2 of the last 10 years in our data. Its share count fell by 57% over three years (buybacks).
Score: 1.0 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19M | $31M | $333763 | -$4M | -$4M | -$4M | -$4M | -$4M | -$7M | -$4M |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-41.55 | $47.85 | $-27.00 | $-3.30 | $-4.05 | $-36.75 | $-63.45 | $0.00 | $-225.00 | $-225.00 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -16.3% | -6.7% | -24.3% | -7.0% | -3.9% | -42.9% | -59.4% | -64.3% | -95.6% | -43.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does PharmaCyte Biotech pay a dividend?
Not currently.
Is PharmaCyte Biotech a good stock to buy?
We do not give buy or sell advice. PharmaCyte Biotech scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.